# An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)

> **NCT00674102** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** ASA404

## Key facts

- **NCT ID:** NCT00674102
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-03
- **Final completion:** —
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00674102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00674102, "An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00674102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*